November 8, 2018 8:12am

In a continuing battle of consensus, expectation and estimates

Quarterly results: by Histogenics (HSGX), BioTime (NTSEMKT: BTX), Applied Genetic Technologies (AGTC), Intrexon (XON), BioLife Solutions (BLFS), Caladrius Bioscience (CLBS) and Biostage (BSTG)

Continuing thematic: “street” expectation – meeting or not?


Pre-open indications: 3 BUYs and 2 SELLs



A trusted source of factual reporting!

You should or could have been reading to facilitate your portfolios ... viability to flourish and produce gains!

Members only. Please login.